Mesoblast Limited MESO
Annual
Quarterly
FY2025 · ended Jun 30, 2025 · Revenue $17.20M, +191.4% YoY · Filed Aug 29, 2025
Mesoblast Limited (MESO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Jun 30, 2025, it reported revenue of $17.2 million and a net loss of $102.1 million. Free cash flow was -$50.6 million. As of Jun 30, 2025 it held $161.6 million in cash and investments and $182.3 million in total debt.
Revenue
$17.20M
+191.4% vs prior year
Net income
$-102.14M
-16.1% vs prior year
Operating cash flow
$-49.95M
-3.1% vs prior year
Free cash flow
$-50.63M
EPS
$-0.08
+5.1% vs prior year
Dividend per share
None
Shares outstanding
1.30B
+1.3% vs prior year
Net cash
$-20.76M
FY 2025
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MESO (Nasdaq), MEOBF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria, Australia
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1345099
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $17.2M | $5.9M | $7.5M | $10.2M | $7.4M |
| Net income | -$102.1M | -$88.0M | -$81.9M | -$91.3M | -$98.8M |
| Diluted EPS | -$0.08 | -$0.09 | -$0.11 | -$0.13 | -$0.16 |
| Operating cash flow | -$50.0M | -$48.5M | -$63.3M | -$65.8M | -$100.7M |
| Free cash flow | -$50.6M | — | — | — | — |
| Total assets | $784.7M | $669.2M | $669.4M | $662.1M | $744.7M |
| Total liabilities | $187.2M | $188.8M | $167.6M | $165.1M | $163.3M |
| Stockholders' equity | $597.4M | $480.4M | $501.8M | $497.0M | $581.4M |
| Cash and investments | $161.6M | $63.0M | $71.3M | $60.4M | $136.9M |
| Total debt | $182.3M | $132.8M | $122.4M | $15.3M | $158.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 16, 2026 | Oct 16, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 24, 2026 |
All 598 Mesoblast Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.